Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19
Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
In the context of COVID-19 pandemic, a report on ivermectin suppression of SARS-CoV-2 viral
replication in cell cultures has been published, and the use of this medication seems to be
potentially useful for the therapy. IVM safety profile and IVM wide spectrum enables to move
forward with the investigation in patients infected by SARS-CoV-2 as a proof-of-concept of
its possible use in the management of patients with COVID-19, given the current pandemic
situation.
Phase:
Phase 2
Details
Lead Sponsor:
Laboratorio Elea Phoenix S.A.
Collaborators:
Centro de Investigación Veterinaria Tandil CIVETAN Hospital de PediatrÃa Prof Dr. Juan P. Garrahan Universidad Nacional de Quilmes Universidad Nacional de Salta